Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10218426 | Autoimmunity Reviews | 2018 | 11 Pages |
Abstract
In conclusion, DOACs are not effective in all APS patients and should not be used routinely in these patients. Randomized controlled trials assessing clinical efficacy and safety as primary endpoints are underway. In the meantime, a registry of APS patients on DOACs could be proposed to establish in which APS subgroups DOACs would be a safe alternative to warfarin.
Keywords
APLVKAVTEINRRCTsDOACAPsRandomized controlled trialsvitamin K antagonistAnticardiolipin antibodyAntiphospholipid antibodiesVenous thromboembolismRecurrent thrombosisArterial thrombosisThrombin generationACLAntiphospholipid syndromeDirect oral anticoagulantDirect oral anticoagulantsSystemic lupus erythematosuslupus anticoagulantSLEInternational Normalized Ratio
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Virginie Dufrost, Jessie Risse, Tatiana Reshetnyak, Maria Satybaldyeva, Yao Du, Xin-Xin Yan, Stella Salta, Grigorios Gerotziafas, Zhi-Cheng Jing, Ismaël Elalamy, Denis Wahl, Stéphane Zuily,